Oxford Cannabinoid Tech.Holdings Notice of Results (9880J)
22 August 2023 - 4:00PM
UK Regulatory
TIDMOCTP
RNS Number : 9880J
Oxford Cannabinoid Tech.Holdings
22 August 2023
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or the "Company")
Notice of Results
&
Analyst and Investor Presentations
Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical
company developing prescription cannabinoid medicines, intends to
announce results for the period ended 30 April 2023 on Thursday 31
August 2023.
Analyst Briefing, 09:30, Thursday 31 August 2023
A briefing for analysts will be held at 09:30 BST on the day of
the results.
Analysts interested in attending OCTP's briefing should contact
Acuitas Communications by emailing oct@acuitascomms.com or by
calling 020 3745 0293.
Investor Presentation, 13:30, Thursday 31 August 2023
A live online presentation to existing and prospective
shareholders will take place at 13:30 BST on Thursday 31 August via
the Investor Meet Company platform.
Questions can be submitted pre-event via the 'Investor Meet
Company' dashboard up until 09:00 the day before the meeting or at
any time during the live presentation. Investors can sign up to
Investor Meet Company for free and add to meet Oxford Cannabinoid
Technologies Holdings plc via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
Investors who already follow OCTP on the Investor Meet Company
platform will automatically receive an invitation to the event.
The Directors of the Company accept responsibility for the
content of this announcement.
ENDS
Enquiries:
O xford Cannabinoid Technologies
Holdings plc +44 (0)20 3034 2820
Clarissa Sowemimo-Coker (CEO) clarissa@oxcantech.com
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Axis Capital Markets Limited
Richard Hutchison +44 (0)20 3026 0320
Acuitas Communications 020 3745 0293 / 07799 767676
Simon Nayyar simon.nayyar@acuitascomms.com
Arthur Dingemans arthur.dingemans@acuitascomms.com
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd (together
the "Group"), a pharmaceutical Group developing prescription
cannabinoid medicines initially targeting the U$ multi-billion
global pain market.
OCTP currently has a portfolio of four drug development
programmes. Its lead compound, OCT461201, will initially target
neuropathic and visceral pain (including irritable bowel syndrome
("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")),
with Phase I clinical trials, aimed at demonstrating safety and
tolerability. Trial results are expected in Q3 2023. The global
market for CIPN alone is currently valued at US$1.61bn and is
forecast to reach US$2.37bn by the year 2027.
OCTP's drug development pipeline comprises both natural and
synthetic compounds, and includes compounds targeting trigeminal
neuralgia, a severe type of face pain, and cannabinoid derivatives
targeting pain and potentially other therapeutic areas. Having
established an exclusive license agreement with Canopy Growth
Corporation for their entire pharmaceutical cannabinoid derivative
library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen
patent families and associated research data.
OCTP has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence. OCTP's portfolio aims to balance risk, value and time
to market, whilst ensuring market exclusivity around all its key
activities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORDFLFLXVLBBBX
(END) Dow Jones Newswires
August 22, 2023 02:00 ET (06:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From May 2023 to May 2024